CJD 11 Nov 2010 : Column 449W-continued UK Parliament
----- Original Message -----
From: Terry S. Singeltary Sr.
To: CJD-L@LISTS.AEGEE.ORG
Cc: BLOODCJD@YAHOOGROUPS.COM ; cjdvoice@yahoogroups.com
Sent: Sunday, November 14, 2010 3:26 PM
Subject: CJD 11 Nov 2010 : Column 449W-continued UK Parliament
11 Nov 2010 : Column 449W—continued
CJD
Huw Irranca-Davies: To ask the Secretary of State for Health what the outcomes were of his Department's workshop for patients, carers and health professionals on Creutzfeldt-Jakob disease held in April 2010; and if he will make a statement. [23099]
Anne Milton: The workshop was specifically for those affected by haemophilia and other bleeding disorders who may be at increased risk of variant Creutzfeldt-Jakob disease (vCJD). It enabled patients, their families and health professionals to hear presentations from a panel of experts about the current state of knowledge of vCJD and the way in which the risk is managed, given the significant scientific uncertainty. Those attending were able to put questions directly to the experts. The Department funded filming of the workshop. A DVD was made available to the Haemophilia Society.
CJD: Research
Jeremy Corbyn: To ask the Secretary of State for Health (1) what research projects his Department has funded in each of the last three years into Creutzfeldt-Jakob disease; and what the outcomes of those projects were; [22953]
(2) in which companies engaged in research into Creutzfeldt-Jakob disease his Department holds shares. [22955]
Anne Milton: Over the last three years, the Department has funded research on variant Creutzfeldt-Jakob disease (vCJD) in the following areas:
surveillance and prevalence of vCJD in the population;
infectivity of vCJD tissues, and aetiology and transmission studies;
improving the safety of blood;
decontamination of surgical instruments; and
development of therapeutics for prion infected patients.
The projects have built largely on previous studies, as part of the Department's overall strategy for addressing key policy questions relating to vCJD. This has enabled the implementation and continuing refinement of measures to reduce the risk of exposure of the population to vCJD.
Research to determine how many people may be carrying infection in the United Kingdom population has resulted in an estimate, based on a sample of around 10,000 tissue samples, giving a wide prevalence range of between 1:1,200 and 1:20,000. Efforts to refine this are under way.
Transmission of vCJD via blood has been proven and measures have been introduced to reduce the risk of contamination of blood and blood products. The potential 11 Nov 2010 : Column 464W for transmission of vCJD via instruments used in neurosurgery, some other surgery and dental procedures remains. Single-use instruments and decontamination guidelines have been introduced to reduce this risk.
The Department does not hold shares in any companies engaged in research into Creutzfeldt-Jakob disease.
http://www.publications.parliament.uk/pa/cm201011/cmhansrd/cm101111/text/101111w0003.htm#10111183000030
Enforcement Report for October 20, 2010
October 20, 2010
PRODUCT
1) Cryoprecipitated AHF. Recall # B-2523-10;
2) Plasma. Recall # B-2524-10;
3) Red Blood Cells. Recall # B-2525-10;
4) Fresh Frozen Plasma. Recall # B-2526-10
CODE
1) Unit: W038508310277;
2) Units: 3127765, W038508310277, 3129157, 4121927;
3) Units: W038508310277, 3129157, 3127765, 4025397, 4121927, 4018030;
4) Units: 4025397, 4018030
RECALLING FIRM/MANUFACTURER
Walter L. Shepeard Community Blood Center, Inc., Augusta, GA, by facsimile on July 22, 2010 and July 28, 2010. Firm initiated recall is complete.
REASON
Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.
VOLUME OF PRODUCT IN COMMERCE
13 units
DISTRIBUTION
GA, MD, SC, Austria, Israel, South Korea, Switzerland
___________________________________
PRODUCT
1) Fresh Frozen Plasma. Recall # B-2531-10;
2) Recovered Plasma. Recall # B-2532-10;
3) Red Blood Cells Leukocytes Reduced. Recall # B-2533-10
CODE
1) Unit: W115910041730;
2) Units: W115910080008, W115910081199;
3) Units: W115910080008, W115910041730, W115910081199
RECALLING FIRM/MANUFACTURER
Central California Blood Center, Fresno, CA, by e-mail on July 19, 2010 and July 23, 2010 and by facsimile on July 23, 2010. Firm initiated recall is complete.
REASON
Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.
VOLUME OF PRODUCT IN COMMERCE
6 units
DISTRIBUTION
Austria, CA
END OF ENFORCEMENT REPORT FOR OCTOBER 20, 2010
#
http://www.fda.gov/Safety/Recalls/EnforcementReports/ucm230357.htm
Enforcement Report for October 13, 2010
October 13, 2010
PRODUCT
1) Red Blood Cells Leukocytes Reduced. Recall # B-2275-10;
2) Recovered Plasma. Recall # B-2276-10;
3) Cryoprecipitated AHF, Pooled. Recall # B-2277-10
CODE
1), 2) and 3) Unit: 6400811
RECALLING FIRM/MANUFACTURER
South Texas Blood & Tissue Center, San Antonio, TX, by fax on April 7, 2010. Firm initiated recall is complete.
REASON
Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.
VOLUME OF PRODUCT IN COMMERCE
3 units
DISTRIBUTION
FL, TX
___________________________________
PRODUCT
Fresh Frozen Plasma. Recall # B-2283-10
CODE
Units: W001606004574; W001606003405
RECALLING FIRM/MANUFACTURER
Department of the Air Force 88th Medical Group SGQC WPAFB, Wright Patterson, AFB, OH, by letter dated April 17, 2008. Firm initiated recall is complete.
REASON
Blood products, collected from a donor who may have warranted deferral for residency in an area at risk for variant Creutzfeldt-Jakob Disease, were distributed.
VOLUME OF PRODUCT IN COMMERCE
2 units
DISTRIBUTION
NJ
___________________________________
PRODUCT
1) Red Blood Cells Leukocytes Reduced. Recall # B-2322-10
2) Fresh Frozen Plasma. Recall # B-2323-10
CODE
1) and 2) Unit: W280310400336
RECALLING FIRM/MANUFACTURER
Upstate New York Transplant Services, Inc., Buffalo, NY, by telephone and fax on June 21, 2010. Firm initiated recall is complete.
REASON
Blood products, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.
VOLUME OF PRODUCT IN COMMERCE
2 units
DISTRIBUTION
NY
___________________________________
PRODUCT
Red Blood Cells. Recall # B-2324-10
CODE
Unit: W121610120511
RECALLING FIRM/MANUFACTURER
The Blood Connection, Inc., Piedmont, SC, by fax and computerized notification system on June 17, 2010. Firm initiated recall is complete.
REASON
Blood product, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), was distributed.
VOLUME OF PRODUCT IN COMMERCE
1 unit
DISTRIBUTION
NY
___________________________________
PRODUCT
Recovered Plasma. Recall # B-2325-10
CODE
Unit: W121610120511
RECALLING FIRM/MANUFACTURER
The Blood Connection, Inc., Piedmont, SC, by fax and computerized notification system on June 17, 2010. Firm initiated recall is complete.
REASON
Blood product, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), was distributed.
VOLUME OF PRODUCT IN COMMERCE
1 unit
DISTRIBUTION
Switzerland
___________________________________
http://www.fda.gov/Safety/Recalls/EnforcementReports/ucm229271.htm
TSS
----- Original Message ----- From: Terry S. Singeltary Sr. To: BLOODCJD@YAHOOGROUPS.COM Sent: Thursday, October 07, 2010 12:58 PM Subject: [BLOODCJD] USA Blood products, collected from a donor who was at risk for vCJD, were distributed END OF ENFORCEMENT REPORT FOR OCTOBER 6, 2010
PRODUCT
1) Plasma Frozen within 24 hours (FP24). Recall # B-2448-10;
2) Red Blood Cells. Recall # B-2449-10;
3) Cryoprecipitated AHF. Recall # B-2450-10;
4) Plasma. Recall # B-2451-10
CODE
1) Units: W038509802210, W038509800965;
2) Units: W038509802210, W038509800965, W038508801111, W038508330725;
3) Unit: W03850830725;
4) Units: W038509801111, W038508330725
RECALLING FIRM/MANUFACTURER
Walter L. Shepeard Community Blood Center, Inc., Augusta, GA, by fax on July 9 and 21, 2010. Firm initiated recall is complete.
REASON
Blood products, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.
VOLUME OF PRODUCT IN COMMERCE
9 units
DISTRIBUTION
Korea, SC, GA
___________________________________
PRODUCT
Recovered Plasma. Recall # B-2306-10
CODE
Unit: W137508110097
RECALLING FIRM/MANUFACTURER
Lane Memorial Blood Bank, Eugene, OR, by fax on June 10, 2010. Firm initiated recall is complete.
REASON
Blood product, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), was distributed.
VOLUME OF PRODUCT IN COMMERCE
1 unit
DISTRIBUTION
KY
___________________________________
PRODUCT
Red Blood Cells (Apheresis) Leukocytes Reduced. Recall # B-2348-10
CODE
Units: W041609075327D (part a and b), 3922801 (part a and b)
RECALLING FIRM/MANUFACTURER
Blood Systems Inc/dba United Blood Services, Meridian, MS, by telephone and fax on May 26, 2010 and May 28, 2010. Firm initiated recall is complete.
REASON
Blood products, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.
VOLUME OF PRODUCT IN COMMERCE
4 units
DISTRIBUTION
MS
___________________________________
PRODUCT
1) Recovered Plasma. Recall # B-2363-10;
2) Cryoprecipitated AHF, Pooled. Recall # B-2364-10;
3) Red Blood Cells Leukocytes Reduced. Recall # B-2365-10
CODE
1) and 3) Units: 2613522, 2578779;
2) Unit: 2578779
RECALLING FIRM/MANUFACTURER
South Texas Blood and Tissue Center, San Antonio, TX, by fax and e-mail on May 5, 2010. Firm initiated recall is complete.
REASON
Blood products, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.
VOLUME OF PRODUCT IN COMMERCE
5 units
DISTRIBUTION
TX
___________________________________
END OF ENFORCEMENT REPORT FOR OCTOBER 6, 2010
#
http://www.fda.gov/Safety/Recalls/EnforcementReports/ucm228605.htm
PRODUCT
Red Blood Cells. Recall # B-2300-10
CODE
Unit: W001607702825
RECALLING FIRM/MANUFACTURER
Recalling Firm: Department of the Air Force, Wright Patterson AFB, OH, by letter dated April 8, 2008.
Manufacturer: Depart of Air Force 88th Medical Group SGQC WPAFB, Wright Patterson AFB, OH. Firm initiated recall is complete.
REASON
Blood product, collected from a donor who was at risk for variant Creutzfeldt-Jakob Disease (vCJD), was distributed.
VOLUME OF PRODUCT IN COMMERCE
1 unit
DISTRIBUTION
Japan
___________________________________
PRODUCT
Recovered Plasma. Recall # B-2302-10
CODE
Units: R08951; P90041; P90041
RECALLING FIRM/MANUFACTURER
Blood Center of Northcentral Wisconsin, Inc., Wausau, WI, by fax on January 2, 2007. Firm initiated recall is complete.
REASON
Blood products, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.
VOLUME OF PRODUCT IN COMMERCE
3 units
DISTRIBUTION
NY
___________________________________
PRODUCT
1) Red Blood Cells Leukocytes Reduced. Recall # B-2338-10;
2) Plasma Frozen. Recall # B-2339-10
CODE
1) and 2) Unit: 5039861
RECALLING FIRM/MANUFACTURER
Community Blood Center, Inc., Appleton, WI, by letter dated September 21, 2007 or by electronic notification on September 21, 2007. Firm initiated recall is complete.
REASON
Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.
VOLUME OF PRODUCT IN COMMERCE
2 units
DISTRIBUTION
WI, Switzerland
___________________________________
END OF ENFORCEMENT REPORT FOR SEPTEMBER 22, 2010
http://www.fda.gov/Safety/Recalls/EnforcementReports/ucm227078.htm
PRODUCT
1) Cryoprecipitated AHF, Pooled. Recall # B-2155-10;
2) Recovered Plasma. Recall # B-2156-10
CODE
1) Unit: W036309907231;
2) Unit: W036309616077
RECALLING FIRM/MANUFACTURER
BloodCenter of Wisconsin, Inc., Milwaukee, WI, by fax and internet on May 5, 2010 and May 13, 2010. Firm initiated recall is complete.
REASON
Blood products, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.
VOLUME OF PRODUCT IN COMMERCE
2 units
DISTRIBUTION
TX, Switzerland
___________________________________
PRODUCT
Red Blood Cells Leukocytes Reduced. Recall # B-2157-10
CODE
Unit: 6371718
RECALLING FIRM/MANUFACTURER
South Texas Blood & Tissue Center, San Antonio, TX, by telephone on January 23, 2010 and by fax on January 25, 2010. Firm initiated recall is complete.
REASON
Blood product, collected from a donor who failed to answer questions regarding risk for vCJD, was distributed.
VOLUME OF PRODUCT IN COMMERCE
1 unit
DISTRIBUTION
TX
___________________________________
PRODUCT
Source Plasma. Recall # B-2212-10
CODE
Units: 09FMOG6851; 09FMOG3410; 09FMOG2756; 09FMOG1418; 09FMOF6640; 09FMOF2642; 09FMOF1554; 09FMOD7746; 09FMOF0063; 09FMOF7599
RECALLING FIRM/MANUFACTURER
BioLife Plasma Service LP, Springfield, MO, by fax on April 1, 2010. Firm initiated recall is complete.
REASON
Blood products, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.
VOLUME OF PRODUCT IN COMMERCE
10 units
DISTRIBUTION
CA
___________________________________
PRODUCT
1) Red Blood Cells Leukocytes Reduced. Recall # B-2213-10;
2) Recovered Plasma. Recall # B-2214
CODE
1) and 2) Unit: 6325245
RECALLING FIRM/MANUFACTURER
South Texas Blood and Tissue Center, San Antonio, TX, by facsimile on February 8, 2010. Firm initiated recall is complete.
REASON
Blood products, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.
VOLUME OF PRODUCT IN COMMERCE
2 units
DISTRIBUTION
FL, TX
___________________________________
END OF ENFORCEMENT REPORT FOR SEPTEMBER 15, 2010
http://www.fda.gov/Safety/Recalls/EnforcementReports/ucm225990.htm
PRODUCT
Source Plasma. Recall # B-2056-10
CODE
Units: FD0500537, FD0502880, FD0503259, FD0509894, FD0515518, FD0516063, FD0517957, FD0518606, FD0522255, FD0523346, FD0523544, FD0524204, FD0524698, FD0525142, FD0525845, FD0526653, FD0526878, FD0527579, FD0527845, FD0528519, FD0528827, FD0529544, FD0529761, FD0530471, FD0530712, FD0531425, FD0531801, FD0532483, FD0532869, FD0537501, FD0537687, FD0538370, FD0543210, FD0546250, FD0546632, FD0547328, FD0547832, FD0548286, FD0548743, FD0549325, FD0549840, FD0550427, FD0551448, FD0551572, FD0552307, FD0553173, FD0553418, FD0554063, FD0554834, FD0555041, FD0559685, FD0560235, FD0560592, FD0561168, FD0561786, FD0562212, FD0562883, FD0563248, FD0564435, FD0564723, FD0565467, FD0565880, FD0566540, FD0567053, FD0567723, FD0567965, FD0568941, FD0569180, FD0570057, FD0571177, FD0571477, FD0572411, FD0572818, FD0573582, FD0573871, FD0574531, FD0576955, FD0577140, FD0579983, FD0580403, FD0581156, FD0581623, FD0582680, FD0583090, FD0584073, FD0584500, FD0585410, FD0586089, FD0586790, FD0587500, FD0588791, FD0589023, FD0590248, FD0590600, FD0591592, FD0592445, FD0593277, FD0593712, FD0594626, FD0595049, FD0596132, FD0596519, FD0597701, FD0598681, FD0599198, FD0600210, FD0600690, FD0601755, FD0602401, FD0603415, FD0603985, FD0605122, FD0608608, FD0609074, FD0609979, FD0610508, FD0611469, FD0612006, FD0612905
RECALLING FIRM/MANUFACTURER
DCI Biologicals LLC, Farmington, NM, by facsimile on September 26, 2009 and electronic mail dated January 15, 2010. Firm initiated recall is complete.
REASON
Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.
VOLUME OF PRODUCT IN COMMERCE
119 units
DISTRIBUTION
NY, UK
___________________________________
END OF ENFORCEMENT REPORT FOR SEPTEMBER 8, 2010
http://www.fda.gov/Safety/Recalls/EnforcementReports/ucm225223.htm
PRODUCT
Source Plasma. Recall # B-2134-10
CODE
Units: 3910020431, 3910019695, 3910018715, 3910018227, 3910017100, 3910016675, 3910015596, 3910015120, 3910014175, 3910013575, 3910012934, 3910012281, 3910010102, 3910009899, 3910007715, 3910007430
RECALLING FIRM/MANUFACTURER
Talecris Plasma Resources, Inc., N Las Vegas, NV, by fax on July 17, 2009. Firm initiated recall is complete.
REASON
Blood products, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.
VOLUME OF PRODUCT IN COMMERCE
16 units
DISTRIBUTION
NC
___________________________________
PRODUCT
1) Red Blood Cells. Recall # B-2215-10;
2) Fresh Frozen Plasma. Recall # B-2216-10
CODE
1) and 2) Unit: 0951592
RECALLING FIRM/MANUFACTURER
Memorial Blood Centers, Saint Paul, MN, by letter on November 5, 2008. Firm initiated recall is complete.
REASON
Blood products, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.
VOLUME OF PRODUCT IN COMMERCE
2 units
DISTRIBUTION
MN
___________________________________
PRODUCT
Recovered Plasma. Recall # B-2217-10
CODE
Unit: 0951592
RECALLING FIRM/MANUFACTURER
Memorial Blood Centers, Saint Paul, MN, by letter on November 5, 2008. Firm initiated recall is complete.
REASON
Blood product, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), was distributed.
VOLUME OF PRODUCT IN COMMERCE
1 unit
DISTRIBUTION
MN
___________________________________
END OF ENFORCEMENT REPORT FOR SEPTEMBER 1, 2010
http://www.fda.gov/Safety/Recalls/EnforcementReports/ucm224723.htm
PRODUCT
1) Plasma Frozen within 24 hours (FP24). Recall # B-2448-10;
2) Red Blood Cells. Recall # B-2449-10;
3) Cryoprecipitated AHF. Recall # B-2450-10;
4) Plasma. Recall # B-2451-10
CODE
1) Units: W038509802210, W038509800965;
2) Units: W038509802210, W038509800965, W038508801111, W038508330725;
3) Unit: W03850830725;
4) Units: W038509801111, W038508330725
RECALLING FIRM/MANUFACTURER
Walter L. Shepeard Community Blood Center, Inc., Augusta, GA, by fax on July 9 and 21, 2010. Firm initiated recall is complete.
REASON
Blood products, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.
VOLUME OF PRODUCT IN COMMERCE
9 units
DISTRIBUTION
Korea, SC, GA
___________________________________
PRODUCT
Recovered Plasma. Recall # B-2306-10
CODE
Unit: W137508110097
RECALLING FIRM/MANUFACTURER
Lane Memorial Blood Bank, Eugene, OR, by fax on June 10, 2010. Firm initiated recall is complete.
REASON
Blood product, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), was distributed.
VOLUME OF PRODUCT IN COMMERCE
1 unit
DISTRIBUTION
KY
___________________________________
PRODUCT
Red Blood Cells (Apheresis) Leukocytes Reduced. Recall # B-2348-10
CODE
Units: W041609075327D (part a and b), 3922801 (part a and b)
RECALLING FIRM/MANUFACTURER
Blood Systems Inc/dba United Blood Services, Meridian, MS, by telephone and fax on May 26, 2010 and May 28, 2010. Firm initiated recall is complete.
REASON
Blood products, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.
VOLUME OF PRODUCT IN COMMERCE
4 units
DISTRIBUTION
MS
___________________________________
PRODUCT
1) Recovered Plasma. Recall # B-2363-10;
2) Cryoprecipitated AHF, Pooled. Recall # B-2364-10;
3) Red Blood Cells Leukocytes Reduced. Recall # B-2365-10
CODE
1) and 3) Units: 2613522, 2578779;
2) Unit: 2578779
RECALLING FIRM/MANUFACTURER
South Texas Blood and Tissue Center, San Antonio, TX, by fax and e-mail on May 5, 2010. Firm initiated recall is complete.
REASON
Blood products, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.
VOLUME OF PRODUCT IN COMMERCE
5 units
DISTRIBUTION
TX
___________________________________
END OF ENFORCEMENT REPORT FOR OCTOBER 6, 2010
#
http://www.fda.gov/Safety/Recalls/EnforcementReports/ucm228605.htm
Tuesday, September 28, 2010
Variant CJD: where has it gone, or has it?
Pract Neurol 2010; 10: 250-251
http://vcjdtransfusion.blogspot.com/2010/09/variant-cjd-where-has-it-gone-or-has-it.html
Transmissible Spongiform Encephalopathies Advisory Committee; Notice of Meeting October 28 and 29, 2010 (COMMENT SUBMISSION)
----- Original Message -----
From: Terry S. Singeltary Sr.
To: william.freas@fda.hhs.gov Cc: rosanna.harvey@fda.hhs.gov ; Emery, Bryan (CBER)
SEE FULL TEXT ;
http://tseac.blogspot.com/2010/09/transmissible-spongiform_14.html
Wednesday, September 08, 2010
Emerging Infectious Diseases: CJD, BSE, SCRAPIE, CWD, PRION, TSE Evaluation to Implementation for Transfusion and Transplantation September 2010
http://vcjdtransfusion.blogspot.com/2010/09/emerging-infectious-diseases-cjd-bse.html
Saturday, July 17, 2010
Variant Creutzfeldt-Jakob disease Ironside JW., Haemophilia.
2010 Jul;16 Suppl 5:175-80 REVIEW ARTICLE
http://vcjdtransfusion.blogspot.com/2010/07/variant-creutzfeldtjakob-disease.html
Monday, August 9, 2010
National Prion Disease Pathology Surveillance Center Cases Examined (July 31, 2010)
(please watch this damning video at the bottom of this url...tss)
http://prionunitusaupdate2008.blogspot.com/2010/08/national-prion-disease-pathology.html
Tuesday, November 02, 2010
BSE - ATYPICAL LESION DISTRIBUTION (RBSE 92-21367) statutory (obex only) diagnostic criteria CVL 1992
http://bse-atypical.blogspot.com/2010/11/bse-atypical-lesion-distribution-rbse.html
TSS
From: Terry S. Singeltary Sr.
To: CJD-L@LISTS.AEGEE.ORG
Cc: BLOODCJD@YAHOOGROUPS.COM ; cjdvoice@yahoogroups.com
Sent: Sunday, November 14, 2010 3:26 PM
Subject: CJD 11 Nov 2010 : Column 449W-continued UK Parliament
11 Nov 2010 : Column 449W—continued
CJD
Huw Irranca-Davies: To ask the Secretary of State for Health what the outcomes were of his Department's workshop for patients, carers and health professionals on Creutzfeldt-Jakob disease held in April 2010; and if he will make a statement. [23099]
Anne Milton: The workshop was specifically for those affected by haemophilia and other bleeding disorders who may be at increased risk of variant Creutzfeldt-Jakob disease (vCJD). It enabled patients, their families and health professionals to hear presentations from a panel of experts about the current state of knowledge of vCJD and the way in which the risk is managed, given the significant scientific uncertainty. Those attending were able to put questions directly to the experts. The Department funded filming of the workshop. A DVD was made available to the Haemophilia Society.
CJD: Research
Jeremy Corbyn: To ask the Secretary of State for Health (1) what research projects his Department has funded in each of the last three years into Creutzfeldt-Jakob disease; and what the outcomes of those projects were; [22953]
(2) in which companies engaged in research into Creutzfeldt-Jakob disease his Department holds shares. [22955]
Anne Milton: Over the last three years, the Department has funded research on variant Creutzfeldt-Jakob disease (vCJD) in the following areas:
surveillance and prevalence of vCJD in the population;
infectivity of vCJD tissues, and aetiology and transmission studies;
improving the safety of blood;
decontamination of surgical instruments; and
development of therapeutics for prion infected patients.
The projects have built largely on previous studies, as part of the Department's overall strategy for addressing key policy questions relating to vCJD. This has enabled the implementation and continuing refinement of measures to reduce the risk of exposure of the population to vCJD.
Research to determine how many people may be carrying infection in the United Kingdom population has resulted in an estimate, based on a sample of around 10,000 tissue samples, giving a wide prevalence range of between 1:1,200 and 1:20,000. Efforts to refine this are under way.
Transmission of vCJD via blood has been proven and measures have been introduced to reduce the risk of contamination of blood and blood products. The potential 11 Nov 2010 : Column 464W for transmission of vCJD via instruments used in neurosurgery, some other surgery and dental procedures remains. Single-use instruments and decontamination guidelines have been introduced to reduce this risk.
The Department does not hold shares in any companies engaged in research into Creutzfeldt-Jakob disease.
http://www.publications.parliament.uk/pa/cm201011/cmhansrd/cm101111/text/101111w0003.htm#10111183000030
Enforcement Report for October 20, 2010
October 20, 2010
PRODUCT
1) Cryoprecipitated AHF. Recall # B-2523-10;
2) Plasma. Recall # B-2524-10;
3) Red Blood Cells. Recall # B-2525-10;
4) Fresh Frozen Plasma. Recall # B-2526-10
CODE
1) Unit: W038508310277;
2) Units: 3127765, W038508310277, 3129157, 4121927;
3) Units: W038508310277, 3129157, 3127765, 4025397, 4121927, 4018030;
4) Units: 4025397, 4018030
RECALLING FIRM/MANUFACTURER
Walter L. Shepeard Community Blood Center, Inc., Augusta, GA, by facsimile on July 22, 2010 and July 28, 2010. Firm initiated recall is complete.
REASON
Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.
VOLUME OF PRODUCT IN COMMERCE
13 units
DISTRIBUTION
GA, MD, SC, Austria, Israel, South Korea, Switzerland
___________________________________
PRODUCT
1) Fresh Frozen Plasma. Recall # B-2531-10;
2) Recovered Plasma. Recall # B-2532-10;
3) Red Blood Cells Leukocytes Reduced. Recall # B-2533-10
CODE
1) Unit: W115910041730;
2) Units: W115910080008, W115910081199;
3) Units: W115910080008, W115910041730, W115910081199
RECALLING FIRM/MANUFACTURER
Central California Blood Center, Fresno, CA, by e-mail on July 19, 2010 and July 23, 2010 and by facsimile on July 23, 2010. Firm initiated recall is complete.
REASON
Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.
VOLUME OF PRODUCT IN COMMERCE
6 units
DISTRIBUTION
Austria, CA
END OF ENFORCEMENT REPORT FOR OCTOBER 20, 2010
#
http://www.fda.gov/Safety/Recalls/EnforcementReports/ucm230357.htm
Enforcement Report for October 13, 2010
October 13, 2010
PRODUCT
1) Red Blood Cells Leukocytes Reduced. Recall # B-2275-10;
2) Recovered Plasma. Recall # B-2276-10;
3) Cryoprecipitated AHF, Pooled. Recall # B-2277-10
CODE
1), 2) and 3) Unit: 6400811
RECALLING FIRM/MANUFACTURER
South Texas Blood & Tissue Center, San Antonio, TX, by fax on April 7, 2010. Firm initiated recall is complete.
REASON
Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.
VOLUME OF PRODUCT IN COMMERCE
3 units
DISTRIBUTION
FL, TX
___________________________________
PRODUCT
Fresh Frozen Plasma. Recall # B-2283-10
CODE
Units: W001606004574; W001606003405
RECALLING FIRM/MANUFACTURER
Department of the Air Force 88th Medical Group SGQC WPAFB, Wright Patterson, AFB, OH, by letter dated April 17, 2008. Firm initiated recall is complete.
REASON
Blood products, collected from a donor who may have warranted deferral for residency in an area at risk for variant Creutzfeldt-Jakob Disease, were distributed.
VOLUME OF PRODUCT IN COMMERCE
2 units
DISTRIBUTION
NJ
___________________________________
PRODUCT
1) Red Blood Cells Leukocytes Reduced. Recall # B-2322-10
2) Fresh Frozen Plasma. Recall # B-2323-10
CODE
1) and 2) Unit: W280310400336
RECALLING FIRM/MANUFACTURER
Upstate New York Transplant Services, Inc., Buffalo, NY, by telephone and fax on June 21, 2010. Firm initiated recall is complete.
REASON
Blood products, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.
VOLUME OF PRODUCT IN COMMERCE
2 units
DISTRIBUTION
NY
___________________________________
PRODUCT
Red Blood Cells. Recall # B-2324-10
CODE
Unit: W121610120511
RECALLING FIRM/MANUFACTURER
The Blood Connection, Inc., Piedmont, SC, by fax and computerized notification system on June 17, 2010. Firm initiated recall is complete.
REASON
Blood product, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), was distributed.
VOLUME OF PRODUCT IN COMMERCE
1 unit
DISTRIBUTION
NY
___________________________________
PRODUCT
Recovered Plasma. Recall # B-2325-10
CODE
Unit: W121610120511
RECALLING FIRM/MANUFACTURER
The Blood Connection, Inc., Piedmont, SC, by fax and computerized notification system on June 17, 2010. Firm initiated recall is complete.
REASON
Blood product, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), was distributed.
VOLUME OF PRODUCT IN COMMERCE
1 unit
DISTRIBUTION
Switzerland
___________________________________
http://www.fda.gov/Safety/Recalls/EnforcementReports/ucm229271.htm
TSS
----- Original Message ----- From: Terry S. Singeltary Sr. To: BLOODCJD@YAHOOGROUPS.COM Sent: Thursday, October 07, 2010 12:58 PM Subject: [BLOODCJD] USA Blood products, collected from a donor who was at risk for vCJD, were distributed END OF ENFORCEMENT REPORT FOR OCTOBER 6, 2010
PRODUCT
1) Plasma Frozen within 24 hours (FP24). Recall # B-2448-10;
2) Red Blood Cells. Recall # B-2449-10;
3) Cryoprecipitated AHF. Recall # B-2450-10;
4) Plasma. Recall # B-2451-10
CODE
1) Units: W038509802210, W038509800965;
2) Units: W038509802210, W038509800965, W038508801111, W038508330725;
3) Unit: W03850830725;
4) Units: W038509801111, W038508330725
RECALLING FIRM/MANUFACTURER
Walter L. Shepeard Community Blood Center, Inc., Augusta, GA, by fax on July 9 and 21, 2010. Firm initiated recall is complete.
REASON
Blood products, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.
VOLUME OF PRODUCT IN COMMERCE
9 units
DISTRIBUTION
Korea, SC, GA
___________________________________
PRODUCT
Recovered Plasma. Recall # B-2306-10
CODE
Unit: W137508110097
RECALLING FIRM/MANUFACTURER
Lane Memorial Blood Bank, Eugene, OR, by fax on June 10, 2010. Firm initiated recall is complete.
REASON
Blood product, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), was distributed.
VOLUME OF PRODUCT IN COMMERCE
1 unit
DISTRIBUTION
KY
___________________________________
PRODUCT
Red Blood Cells (Apheresis) Leukocytes Reduced. Recall # B-2348-10
CODE
Units: W041609075327D (part a and b), 3922801 (part a and b)
RECALLING FIRM/MANUFACTURER
Blood Systems Inc/dba United Blood Services, Meridian, MS, by telephone and fax on May 26, 2010 and May 28, 2010. Firm initiated recall is complete.
REASON
Blood products, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.
VOLUME OF PRODUCT IN COMMERCE
4 units
DISTRIBUTION
MS
___________________________________
PRODUCT
1) Recovered Plasma. Recall # B-2363-10;
2) Cryoprecipitated AHF, Pooled. Recall # B-2364-10;
3) Red Blood Cells Leukocytes Reduced. Recall # B-2365-10
CODE
1) and 3) Units: 2613522, 2578779;
2) Unit: 2578779
RECALLING FIRM/MANUFACTURER
South Texas Blood and Tissue Center, San Antonio, TX, by fax and e-mail on May 5, 2010. Firm initiated recall is complete.
REASON
Blood products, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.
VOLUME OF PRODUCT IN COMMERCE
5 units
DISTRIBUTION
TX
___________________________________
END OF ENFORCEMENT REPORT FOR OCTOBER 6, 2010
#
http://www.fda.gov/Safety/Recalls/EnforcementReports/ucm228605.htm
PRODUCT
Red Blood Cells. Recall # B-2300-10
CODE
Unit: W001607702825
RECALLING FIRM/MANUFACTURER
Recalling Firm: Department of the Air Force, Wright Patterson AFB, OH, by letter dated April 8, 2008.
Manufacturer: Depart of Air Force 88th Medical Group SGQC WPAFB, Wright Patterson AFB, OH. Firm initiated recall is complete.
REASON
Blood product, collected from a donor who was at risk for variant Creutzfeldt-Jakob Disease (vCJD), was distributed.
VOLUME OF PRODUCT IN COMMERCE
1 unit
DISTRIBUTION
Japan
___________________________________
PRODUCT
Recovered Plasma. Recall # B-2302-10
CODE
Units: R08951; P90041; P90041
RECALLING FIRM/MANUFACTURER
Blood Center of Northcentral Wisconsin, Inc., Wausau, WI, by fax on January 2, 2007. Firm initiated recall is complete.
REASON
Blood products, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.
VOLUME OF PRODUCT IN COMMERCE
3 units
DISTRIBUTION
NY
___________________________________
PRODUCT
1) Red Blood Cells Leukocytes Reduced. Recall # B-2338-10;
2) Plasma Frozen. Recall # B-2339-10
CODE
1) and 2) Unit: 5039861
RECALLING FIRM/MANUFACTURER
Community Blood Center, Inc., Appleton, WI, by letter dated September 21, 2007 or by electronic notification on September 21, 2007. Firm initiated recall is complete.
REASON
Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.
VOLUME OF PRODUCT IN COMMERCE
2 units
DISTRIBUTION
WI, Switzerland
___________________________________
END OF ENFORCEMENT REPORT FOR SEPTEMBER 22, 2010
http://www.fda.gov/Safety/Recalls/EnforcementReports/ucm227078.htm
PRODUCT
1) Cryoprecipitated AHF, Pooled. Recall # B-2155-10;
2) Recovered Plasma. Recall # B-2156-10
CODE
1) Unit: W036309907231;
2) Unit: W036309616077
RECALLING FIRM/MANUFACTURER
BloodCenter of Wisconsin, Inc., Milwaukee, WI, by fax and internet on May 5, 2010 and May 13, 2010. Firm initiated recall is complete.
REASON
Blood products, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.
VOLUME OF PRODUCT IN COMMERCE
2 units
DISTRIBUTION
TX, Switzerland
___________________________________
PRODUCT
Red Blood Cells Leukocytes Reduced. Recall # B-2157-10
CODE
Unit: 6371718
RECALLING FIRM/MANUFACTURER
South Texas Blood & Tissue Center, San Antonio, TX, by telephone on January 23, 2010 and by fax on January 25, 2010. Firm initiated recall is complete.
REASON
Blood product, collected from a donor who failed to answer questions regarding risk for vCJD, was distributed.
VOLUME OF PRODUCT IN COMMERCE
1 unit
DISTRIBUTION
TX
___________________________________
PRODUCT
Source Plasma. Recall # B-2212-10
CODE
Units: 09FMOG6851; 09FMOG3410; 09FMOG2756; 09FMOG1418; 09FMOF6640; 09FMOF2642; 09FMOF1554; 09FMOD7746; 09FMOF0063; 09FMOF7599
RECALLING FIRM/MANUFACTURER
BioLife Plasma Service LP, Springfield, MO, by fax on April 1, 2010. Firm initiated recall is complete.
REASON
Blood products, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.
VOLUME OF PRODUCT IN COMMERCE
10 units
DISTRIBUTION
CA
___________________________________
PRODUCT
1) Red Blood Cells Leukocytes Reduced. Recall # B-2213-10;
2) Recovered Plasma. Recall # B-2214
CODE
1) and 2) Unit: 6325245
RECALLING FIRM/MANUFACTURER
South Texas Blood and Tissue Center, San Antonio, TX, by facsimile on February 8, 2010. Firm initiated recall is complete.
REASON
Blood products, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.
VOLUME OF PRODUCT IN COMMERCE
2 units
DISTRIBUTION
FL, TX
___________________________________
END OF ENFORCEMENT REPORT FOR SEPTEMBER 15, 2010
http://www.fda.gov/Safety/Recalls/EnforcementReports/ucm225990.htm
PRODUCT
Source Plasma. Recall # B-2056-10
CODE
Units: FD0500537, FD0502880, FD0503259, FD0509894, FD0515518, FD0516063, FD0517957, FD0518606, FD0522255, FD0523346, FD0523544, FD0524204, FD0524698, FD0525142, FD0525845, FD0526653, FD0526878, FD0527579, FD0527845, FD0528519, FD0528827, FD0529544, FD0529761, FD0530471, FD0530712, FD0531425, FD0531801, FD0532483, FD0532869, FD0537501, FD0537687, FD0538370, FD0543210, FD0546250, FD0546632, FD0547328, FD0547832, FD0548286, FD0548743, FD0549325, FD0549840, FD0550427, FD0551448, FD0551572, FD0552307, FD0553173, FD0553418, FD0554063, FD0554834, FD0555041, FD0559685, FD0560235, FD0560592, FD0561168, FD0561786, FD0562212, FD0562883, FD0563248, FD0564435, FD0564723, FD0565467, FD0565880, FD0566540, FD0567053, FD0567723, FD0567965, FD0568941, FD0569180, FD0570057, FD0571177, FD0571477, FD0572411, FD0572818, FD0573582, FD0573871, FD0574531, FD0576955, FD0577140, FD0579983, FD0580403, FD0581156, FD0581623, FD0582680, FD0583090, FD0584073, FD0584500, FD0585410, FD0586089, FD0586790, FD0587500, FD0588791, FD0589023, FD0590248, FD0590600, FD0591592, FD0592445, FD0593277, FD0593712, FD0594626, FD0595049, FD0596132, FD0596519, FD0597701, FD0598681, FD0599198, FD0600210, FD0600690, FD0601755, FD0602401, FD0603415, FD0603985, FD0605122, FD0608608, FD0609074, FD0609979, FD0610508, FD0611469, FD0612006, FD0612905
RECALLING FIRM/MANUFACTURER
DCI Biologicals LLC, Farmington, NM, by facsimile on September 26, 2009 and electronic mail dated January 15, 2010. Firm initiated recall is complete.
REASON
Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.
VOLUME OF PRODUCT IN COMMERCE
119 units
DISTRIBUTION
NY, UK
___________________________________
END OF ENFORCEMENT REPORT FOR SEPTEMBER 8, 2010
http://www.fda.gov/Safety/Recalls/EnforcementReports/ucm225223.htm
PRODUCT
Source Plasma. Recall # B-2134-10
CODE
Units: 3910020431, 3910019695, 3910018715, 3910018227, 3910017100, 3910016675, 3910015596, 3910015120, 3910014175, 3910013575, 3910012934, 3910012281, 3910010102, 3910009899, 3910007715, 3910007430
RECALLING FIRM/MANUFACTURER
Talecris Plasma Resources, Inc., N Las Vegas, NV, by fax on July 17, 2009. Firm initiated recall is complete.
REASON
Blood products, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.
VOLUME OF PRODUCT IN COMMERCE
16 units
DISTRIBUTION
NC
___________________________________
PRODUCT
1) Red Blood Cells. Recall # B-2215-10;
2) Fresh Frozen Plasma. Recall # B-2216-10
CODE
1) and 2) Unit: 0951592
RECALLING FIRM/MANUFACTURER
Memorial Blood Centers, Saint Paul, MN, by letter on November 5, 2008. Firm initiated recall is complete.
REASON
Blood products, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.
VOLUME OF PRODUCT IN COMMERCE
2 units
DISTRIBUTION
MN
___________________________________
PRODUCT
Recovered Plasma. Recall # B-2217-10
CODE
Unit: 0951592
RECALLING FIRM/MANUFACTURER
Memorial Blood Centers, Saint Paul, MN, by letter on November 5, 2008. Firm initiated recall is complete.
REASON
Blood product, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), was distributed.
VOLUME OF PRODUCT IN COMMERCE
1 unit
DISTRIBUTION
MN
___________________________________
END OF ENFORCEMENT REPORT FOR SEPTEMBER 1, 2010
http://www.fda.gov/Safety/Recalls/EnforcementReports/ucm224723.htm
PRODUCT
1) Plasma Frozen within 24 hours (FP24). Recall # B-2448-10;
2) Red Blood Cells. Recall # B-2449-10;
3) Cryoprecipitated AHF. Recall # B-2450-10;
4) Plasma. Recall # B-2451-10
CODE
1) Units: W038509802210, W038509800965;
2) Units: W038509802210, W038509800965, W038508801111, W038508330725;
3) Unit: W03850830725;
4) Units: W038509801111, W038508330725
RECALLING FIRM/MANUFACTURER
Walter L. Shepeard Community Blood Center, Inc., Augusta, GA, by fax on July 9 and 21, 2010. Firm initiated recall is complete.
REASON
Blood products, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.
VOLUME OF PRODUCT IN COMMERCE
9 units
DISTRIBUTION
Korea, SC, GA
___________________________________
PRODUCT
Recovered Plasma. Recall # B-2306-10
CODE
Unit: W137508110097
RECALLING FIRM/MANUFACTURER
Lane Memorial Blood Bank, Eugene, OR, by fax on June 10, 2010. Firm initiated recall is complete.
REASON
Blood product, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), was distributed.
VOLUME OF PRODUCT IN COMMERCE
1 unit
DISTRIBUTION
KY
___________________________________
PRODUCT
Red Blood Cells (Apheresis) Leukocytes Reduced. Recall # B-2348-10
CODE
Units: W041609075327D (part a and b), 3922801 (part a and b)
RECALLING FIRM/MANUFACTURER
Blood Systems Inc/dba United Blood Services, Meridian, MS, by telephone and fax on May 26, 2010 and May 28, 2010. Firm initiated recall is complete.
REASON
Blood products, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.
VOLUME OF PRODUCT IN COMMERCE
4 units
DISTRIBUTION
MS
___________________________________
PRODUCT
1) Recovered Plasma. Recall # B-2363-10;
2) Cryoprecipitated AHF, Pooled. Recall # B-2364-10;
3) Red Blood Cells Leukocytes Reduced. Recall # B-2365-10
CODE
1) and 3) Units: 2613522, 2578779;
2) Unit: 2578779
RECALLING FIRM/MANUFACTURER
South Texas Blood and Tissue Center, San Antonio, TX, by fax and e-mail on May 5, 2010. Firm initiated recall is complete.
REASON
Blood products, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed.
VOLUME OF PRODUCT IN COMMERCE
5 units
DISTRIBUTION
TX
___________________________________
END OF ENFORCEMENT REPORT FOR OCTOBER 6, 2010
#
http://www.fda.gov/Safety/Recalls/EnforcementReports/ucm228605.htm
Tuesday, September 28, 2010
Variant CJD: where has it gone, or has it?
Pract Neurol 2010; 10: 250-251
http://vcjdtransfusion.blogspot.com/2010/09/variant-cjd-where-has-it-gone-or-has-it.html
Transmissible Spongiform Encephalopathies Advisory Committee; Notice of Meeting October 28 and 29, 2010 (COMMENT SUBMISSION)
----- Original Message -----
From: Terry S. Singeltary Sr.
To: william.freas@fda.hhs.gov Cc: rosanna.harvey@fda.hhs.gov ; Emery, Bryan (CBER)
SEE FULL TEXT ;
http://tseac.blogspot.com/2010/09/transmissible-spongiform_14.html
Wednesday, September 08, 2010
Emerging Infectious Diseases: CJD, BSE, SCRAPIE, CWD, PRION, TSE Evaluation to Implementation for Transfusion and Transplantation September 2010
http://vcjdtransfusion.blogspot.com/2010/09/emerging-infectious-diseases-cjd-bse.html
Saturday, July 17, 2010
Variant Creutzfeldt-Jakob disease Ironside JW., Haemophilia.
2010 Jul;16 Suppl 5:175-80 REVIEW ARTICLE
http://vcjdtransfusion.blogspot.com/2010/07/variant-creutzfeldtjakob-disease.html
Monday, August 9, 2010
National Prion Disease Pathology Surveillance Center Cases Examined (July 31, 2010)
(please watch this damning video at the bottom of this url...tss)
http://prionunitusaupdate2008.blogspot.com/2010/08/national-prion-disease-pathology.html
Tuesday, November 02, 2010
BSE - ATYPICAL LESION DISTRIBUTION (RBSE 92-21367) statutory (obex only) diagnostic criteria CVL 1992
http://bse-atypical.blogspot.com/2010/11/bse-atypical-lesion-distribution-rbse.html
TSS
posted by Terry S. Singeltary Sr. at
3:28 PM
<< Home